Novo Nordisk reshuffles executive team after Camilla Sylvest departs

Novo Nordisk announced a reorganization of its executive leadership team effective April 3, 2025, after Camilla Sylvest, executive vice president of Commercial Strategy & Corporate Affairs, left the company at the end of a 28-year career there ^[1].

Ludovic Helfgott, previously executive vice president of Rare Disease, takes on a broader role overseeing Product & Portfolio Strategy, covering commercial strategy, medical affairs and business development across all of the company's therapy areas ^[1]. Helfgott joined Novo Nordisk in 2019 from AstraZeneca and led the build-out of the company's rare disease portfolio, according to the announcement ^[1].

Two other executives also take on expanded roles. Thilde Hummel Bøgebjerg, an 18-year Novo Nordisk veteran, was promoted to executive vice president of Quality, IT & Environmental Affairs ^[1]. Tania Sabroe, who heads People & Organisation, will additionally lead Global Communication ^[1].

The changes were described as helping Novo Nordisk manage high demand for its GLP-1 therapies while strengthening its rare disease division, which the announcement calls a priority for CEO Lars Fruergaard Jørgensen ^[1]. Novo Nordisk makes the semaglutide medicines Ozempic, Wegovy and Rybelsus.

The company did not disclose the full list of the updated executive team, and the size of that group has not been reported. The announcement also did not say whether any of the departing or reassigned executives had direct responsibility for the GLP-1 products, or name a successor to Sylvest's commercial strategy duties beyond Helfgott's expanded portfolio.

Why it matters for patients

Treatment decisions for people taking semaglutide rest with their prescribers, but the business side of Novo Nordisk shapes things patients do notice: whether pharmacies can refill a prescription, what a health plan covers, and how a manufacturer runs patient support programs. This reshuffle places commercial strategy, medical affairs and business development under one executive ^[1], which concentrates decisions about how the company markets and supports its medicines.

Nothing in the announcement describes changes to manufacturing, supply, pricing, insurance coverage or patient assistance programs, and no such changes have been reported. Whether the new structure affects refill availability, formulary negotiations or support services for people taking Ozempic, Wegovy or Rybelsus is not yet known.

The timing is notable because the reorganization is tied in the announcement to high demand for the company's GLP-1 therapies ^[1]. Novo Nordisk has not said that demand has eased or worsened, or that the leadership change is a response to any specific supply or access problem.

For patients on other Novo Nordisk medicines, the emphasis on rare disease is a second thread. Helfgott, who built that portfolio, now has a wider brief rather than losing it ^[1], and the company says strengthening rare disease remains a priority under its CEO ^[1]. What that means in funding or staffing has not been disclosed.

What happens next

No further milestones were announced with this change beyond its April 3, 2025 effective date ^[1]. The company has not said when it will name a permanent replacement for the commercial strategy and corporate affairs duties Sylvest held, and it has not disclosed a timeline for any additional management changes.